SIGA TECHNOLOGIES Business Summary

SIGA Technologies Inc. (SIGA) is a commercial-stage pharmaceutical company specializing in the global health security market, primarily generating revenue through high-value procurement contracts with government agencies for its flagship antiviral, TPOXX (tecovirimat). The company’s business model is anchored by long-term supply agreements with the U.S. Department of Health and Human Services (BARDA) and the Department of Defense to maintain the Strategic National Stockpile (SNS) against smallpox and other orthopoxviruses. Revenue is bifurcated into two primary segments: product sales of oral and intravenous TPOXX formulations to domestic and international governments, and research and development (R&D) services funded by federal grants for pediatric development and post-exposure prophylaxis indications. SIGA maintains a dominant niche position as the provider of the only FDA-approved oral smallpox treatment, competing primarily against biodefense and antiviral peers such as Chimerix, Emergent BioSolutions, Bavarian Nordic, and Aurinia Pharmaceuticals. Originally founded in 1995 with an initial leadership team led by Dr. Donald P. D'Alessio, SIGA is currently directed by a seasoned executive team with deep pedigree in global pharmaceuticals and finance. Chief Executive Officer Dr. Diem Nguyen, appointed in early 2024, previously served as a Global President at Pfizer, where she managed business units generating over $11 billion in annual revenue. She is supported by Executive VP and CFO Daniel J. Luckshire, a former Merrill Lynch investment banker who has overseen the company’s financial strategy since 2011, and Chief Scientific Officer Dr. Dennis Hruby, a veteran virologist with over 200 publications who has led SIGA’s R&D since 2000. The company’s strategic direction is further influenced by a high-profile board of directors, including Chairman Dr. Eric Rose and retired four-star General John "Jack" Keane, with billionaire Ronald Perelman’s MacAndrews & Forbes Inc. remaining the most notable majority shareholder.